Home

Artelo Biosciences, Inc. - Common Stock (ARTL)

9.5000
-3.7700 (-28.41%)
NASDAQ · Last Trade: Jul 1st, 6:55 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close13.27
Open11.12
Bid9.580
Ask9.850
Day's Range9.110 - 11.81
52 Week Range4.918 - 25.58
Volume532,689
Market Cap31.17M
PE Ratio (TTM)-4.241
EPS (TTM)-2.2
Dividend & YieldN/A (N/A)
1 Month Average Volume1,361,997

Chart

About Artelo Biosciences, Inc. - Common Stock (ARTL)

Artelo Biosciences Inc is a biopharmaceutical company focused on developing innovative therapies to address unmet medical needs, particularly in the fields of oncology and pain management. The company is dedicated to advancing its proprietary drug candidates that target the endocannabinoid system, aiming to improve patients’ quality of life and treatment outcomes. Through its research and development efforts, Artelo seeks to harness the therapeutic potential of cannabinoids and related compounds, striving to bring new solutions to difficult-to-treat conditions. Read More

News & Press Releases

Which stocks are moving on Tuesday?chartmill.com
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Via Chartmill · July 1, 2025
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga.com
Via Benzinga · July 1, 2025
Which stocks are experiencing notable movement on Tuesday?chartmill.com
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Via Chartmill · July 1, 2025
Recap: Artelo Biosciences Q4 Earningsbenzinga.com
Via Benzinga · March 25, 2024
Recap: Artelo Biosciences Q3 Earningsbenzinga.com
Via Benzinga · November 13, 2023
Get insights into the top gainers and losers of Tuesday's pre-market session.chartmill.com
Wondering what's happening in Tuesday's pre-market session? Find an overview in this article.
Via Chartmill · July 1, 2025
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · July 1, 2025
Why Thumzup Media Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · July 1, 2025
Synergy CHC Corp. (NASDAQ: SNYR) Secures Distribution Wins for FOCUSfactor® Supplements and Functional Beverages – More Stocks Inside
Synergy CHC Corp. (NASDAQ: SNYR), a rising consumer staple health company, has announced a wave of major expansion throughout North American for its FOCUSfactor® supplements and functional beverage brands, across mass, grocery, convenience, and wholesale channels. Functional Beverage Momentum
Via AB Newswire · June 30, 2025
These stocks are moving in today's after hours sessionchartmill.com
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via Chartmill · June 30, 2025
Artelo Biosciences Stock Doubles After Positive Results In First Non-Opioid Pain Treatment Trialstocktwits.com
The company said that a multiple ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of ART26.12 with repeated dosing over time is expected to commence in the fourth quarter this year.
Via Stocktwits · June 30, 2025
Crude Oil Moves Lower; Joby Aviation Shares Surgebenzinga.com
Via Benzinga · June 30, 2025
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga.com
Via Benzinga · June 30, 2025
Dow Gains Over 100 Points; Chicago PMI Weakens In Junebenzinga.com
Via Benzinga · June 30, 2025
Why Is Micro-Cap Artelo Biosciences Stock Trading Higher On Monday?benzinga.com
Artelo reports favorable Phase 1 results for its FABP5 inhibitor, showing strong safety data and dose-dependent absorption in 49 healthy participants.
Via Benzinga · June 30, 2025
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · June 30, 2025
This UnitedHealth Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesdaybenzinga.com
Via Benzinga · June 11, 2025
EXCLUSIVE: Artelo Biosciences' New Peer-Reviewed Research Shows Effectiveness Of Psoriasis Candidate In Animal Modelsbenzinga.com
Artelo Biosciences advances ART26.12 for psoriasis and CIPN, while ART27.13 shows early promise in cancer-related anorexia studies.
Via Benzinga · April 28, 2025
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga.com
Via Benzinga · April 23, 2025
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · April 14, 2025
EXCLUSIVE: Artelo Biosciences Concludes First Cohort Of Healthy Volunteers Of FABP Inhibitor Programbenzinga.com
Artelo Biosciences advances its pipeline with ART26.12 for neuropathic pain and ART27.13 for cancer-related anorexia, targeting 2025 milestones.
Via Benzinga · January 13, 2025
ARTL Stock Earnings: Artelo Biosciences Beats EPS for Q2 2024investorplace.com
ARTL stock results show that Artelo Biosciences beat analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 13, 2024
ARTL Stock Earnings: Artelo Biosciences Beats EPS for Q1 2024investorplace.com
ARTL stock results show that Artelo Biosciences beat analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 13, 2024
ARTL Stock Earnings: Artelo Biosciences Misses EPS for Q4 2023investorplace.com
ARTL stock results show that Artelo Biosciences missed analyst estimates for earnings per share the fourth quarter of 2023.
Via InvestorPlace · March 25, 2024
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga.com
Via Benzinga · March 6, 2024